Hot Investor Mandate 4: China Investment Firm Dedicates $100 Million Fund to US Pharma and Medtech Opportunities

12 Oct

A China-based firm invests from a US$700M healthcare fund with an investment strategy focused on global growth opportunities. The company’s US offices have a US$100M VC fund focused on Seed to Series A opportunities in healthcare. Typical early-stage investment through the fund is US$5-10M. The firm prefers to lead in a financing round but is also open to co-investing. The firm is currently seeking opportunities from the US, China Europe and Israel.

When it comes to early-stage healthcare investments, the firm is extremely opportunistic across sectors. The firm’s focus is divided between 80 percent pharma and biotech, reserving 20 percent for devices, health care IT and services. In terms of disease areas, the firm prefers technologies targeting large unmet medical need and is less interested in rare diseases. The firm is seeking opportunities in Seed or Series A stage.

The firm is looking for experienced teams with strong sector expertise. As a China-based fund, the firm seeks to add value in the Chinese market through joint venture, registration expertise, and distribution channels.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: